ST. CLOUD HOSPITAL
- Type
- Teaching hospital
- Where
- Sartell, MN
- Medicare CCN
- 240036
- Received
- $1,029,535 in 159 records, 2022 ($3,775 general, $1,025,760 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: St. Cloud Hospital Fuzzy (name and state)
- Business registration: St. Cloud Hospital DBA St. Benedict's Senior Community - Chateau Waters Fuzzy (name and state)
- Nonprofit contractor: St Cloud Hospital Fuzzy (name and state)
- Nonprofit: ST CLOUD HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 5 | $3,775 |
| 2022 | Research payment | 154 | $1,025,760 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ENDOTRONIX, INC. | 1 | $301,711 | 2022 |
| Edwards Lifesciences Corporation | 9 | $191,381 | 2022 |
| Boston Scientific Corporation | 32 | $164,806 | 2022 |
| Cardiovascular Systems Inc. | 16 | $92,543 | 2022 |
| Medtronic, Inc. | 14 | $74,427 | 2022 |
| Novartis Pharmaceuticals Corporation | 1 | $47,831 | 2022 |
| PFIZER INC. | 13 | $42,080 | 2022 |
| Abbott Laboratories | 19 | $31,179 | 2022 |
| Esperion Therapeutics, Inc. | 36 | $19,357 | 2022 |
| Eli Lilly and Company | 2 | $18,002 | 2022 |
| Amgen Inc. | 2 | $12,113 | 2022 |
| AstraZeneca Pharmaceuticals LP | 2 | $11,062 | 2022 |
| AstraZeneca UK Limited | 1 | $8,842 | 2022 |
| Stryker Corporation | 6 | $6,113 | 2022 |
| Acerta Pharma LLC | 1 | $5,421 | 2022 |
| Siemens Medical Solutions USA, Inc. | 1 | $1,474 | 2022 |
| Medline Industries LP | 3 | $1,187 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 154 | $1,025,760 |
| Debt forgiveness | 3 | $2,718 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 2 | $1,057 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | ENDOTRONIX, INC. | $301,711 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2022 |
| 2022-12-31 | Siemens Medical Solutions USA, Inc. | $1,474 | Debt forgiveness | In-kind items and services | 2022 | ||
| 2022-12-31 | Stryker Corporation | $1,113 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-31 | Medline Industries LP | $130 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-12-29 | PFIZER INC. | $19,650 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $5,692 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $1,067 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-12-12 | Edwards Lifesciences Corporation | $31,718 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-12-12 | Medtronic, Inc. | $2,385 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-12 | Medtronic, Inc. | $1,113 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-12-01 | Cardiovascular Systems Inc. | $130 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-11-30 | Edwards Lifesciences Corporation | $1,679 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-11-21 | Boston Scientific Corporation | $521 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-11-17 | Stryker Corporation | $250 | Research payment | Cash or cash equivalent | T2 ALPHA Device, TRAUMA & EXTREMITIES | A POST-MARKET CLINICAL EVALUATION OF THE TREATMENT OF FEMUR FRACTURES WITH THE FEMORAL NAIL PIRIFORMIS FOSSA (PF) OF TH | 2022 |
| 2022-11-17 | Stryker Corporation | $250 | Research payment | Cash or cash equivalent | T2 ALPHA Device, TRAUMA & EXTREMITIES | A POST-MARKET CLINICAL EVALUATION OF THE TREATMENT OF FEMUR FRACTURES WITH THE FEMORAL NAIL GREATER TROCHANTER (GT) OF T | 2022 |
| 2022-11-16 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-11-09 | Abbott Laboratories | $1,410 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-11-09 | Abbott Laboratories | $656 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-11-07 | Boston Scientific Corporation | $2,740 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-11-04 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-11-02 | Abbott Laboratories | $3,155 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-11-02 | Abbott Laboratories | $661 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Amplatzer Amulet LAAO vs. NOAC (CATALYST) | 2022 |
| 2022-11-01 | Cardiovascular Systems Inc. | $715 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-10-20 | Edwards Lifesciences Corporation | $42,419 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2022 | |
| 2022-10-19 | Medtronic, Inc. | $18,662 | Research payment | Cash or cash equivalent | RESOLUTE ONYX Device, Stents | PSR-Coronary | 2022 |
| 2022-10-17 | Boston Scientific Corporation | $10,512 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-10-17 | Boston Scientific Corporation | $1,220 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
| 2022-10-14 | Cardiovascular Systems Inc. | $6,689 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-10-13 | Edwards Lifesciences Corporation | $73,179 | Research payment | Cash or cash equivalent | The PROGRESS Trial 2021-01 | 2022 | |
| 2022-10-03 | Cardiovascular Systems Inc. | $227 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-09-29 | Medtronic, Inc. | $10,543 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $1,984 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-09-20 | PFIZER INC. | $1,090 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-09-20 | Boston Scientific Corporation | $638 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-09-15 | Medtronic, Inc. | $3,134 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-15 | Medtronic, Inc. | $1,590 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-09-01 | Cardiovascular Systems Inc. | $292 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-23 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-17 | Abbott Laboratories | $1,573 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Amplatzer Amulet LAAO vs. NOAC (CATALYST) | 2022 |
| 2022-08-16 | Boston Scientific Corporation | $3,710 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-08-16 | Boston Scientific Corporation | $2,563 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-08-15 | Edwards Lifesciences Corporation | $7,245 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2022 | |
| 2022-08-10 | Abbott Laboratories | $1,093 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-08-01 | Cardiovascular Systems Inc. | $227 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $338 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-18 | Boston Scientific Corporation | $15,684 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-07-18 | Boston Scientific Corporation | $375 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-07-14 | Cardiovascular Systems Inc. | $24,372 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-07-13 | Abbott Laboratories | $787 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-07-07 | Edwards Lifesciences Corporation | $16,716 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-07-07 | Edwards Lifesciences Corporation | $7,800 | Research payment | Cash or cash equivalent | ALLIANCE 2021-05 | 2022 | |
| 2022-07-06 | Abbott Laboratories | $40 | Research payment | In-kind items and services | CARDIOMEMS Device, Heart Failure | Validation of CardioMEMS HF System Cardiac Output Algorithm IDE (VICTOR) | 2022 |
| 2022-07-06 | Abbott Laboratories | $35 | Research payment | In-kind items and services | CARDIOMEMS Device, Heart Failure | Validation of CardioMEMS HF System Cardiac Output Algorithm IDE (VICTOR) | 2022 |
| 2022-07-01 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-07-01 | Cardiovascular Systems Inc. | $487 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-06-29 | Medline Industries LP | $796 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MEDLINE RENEWAL Medical Supply, REPROCESSING | 2022 | |
| 2022-06-21 | Boston Scientific Corporation | $5,983 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-06-21 | Boston Scientific Corporation | $2,144 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $1,238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-21 | Esperion Therapeutics, Inc. | $338 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-20 | Medline Industries LP | $260 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MEDLINE RENEWAL Medical Supply, REPROCESSING | 2022 | |
| 2022-06-16 | Medtronic, Inc. | $1,908 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-06-16 | Medtronic, Inc. | $1,200 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-06-02 | Esperion Therapeutics, Inc. | $613 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-02 | Esperion Therapeutics, Inc. | $613 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-02 | Esperion Therapeutics, Inc. | $613 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-02 | Esperion Therapeutics, Inc. | $613 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-02 | Esperion Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-01 | Cardiovascular Systems Inc. | $390 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-05-25 | Abbott Laboratories | $4,148 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-05-23 | Edwards Lifesciences Corporation | $2,822 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2022 | |
| 2022-05-16 | Boston Scientific Corporation | $17,430 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-05-16 | Boston Scientific Corporation | $473 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-05-13 | PFIZER INC. | $1,090 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-05-04 | Abbott Laboratories | $422 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-05-04 | Abbott Laboratories | $165 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Amplatzer Amulet LAAO vs. NOAC (CATALYST) | 2022 |
| 2022-05-02 | Cardiovascular Systems Inc. | $292 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-04-27 | Abbott Laboratories | $2,568 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-04-26 | Novartis Pharmaceuticals Corporation | $47,831 | Research payment | Cash or cash equivalent | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL, ASSESSING THE IMPACT OF INCLISIRAN ON MAJOR ADVERSE CAR | 2022 | |
| 2022-04-21 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-18 | Boston Scientific Corporation | $11,892 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-04-18 | Boston Scientific Corporation | $905 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-04-18 | Boston Scientific Corporation | $456 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-04-14 | Medtronic, Inc. | $26,075 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2022 |
| 2022-04-14 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-04-11 | PFIZER INC. | $5,400 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-04-08 | Cardiovascular Systems Inc. | $22,641 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-04-01 | Cardiovascular Systems Inc. | $747 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-03-24 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-03-22 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-03-22 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2022 |
| 2022-03-21 | Boston Scientific Corporation | $11,935 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-03-17 | AstraZeneca UK Limited | $8,842 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Le | 2022 |
| 2022-03-17 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-17 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-16 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-03-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-03-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-03-07 | Boston Scientific Corporation | $6,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | SWAN | 2022 |
| 2022-03-03 | Medtronic, Inc. | $4,954 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-03-03 | Medtronic, Inc. | $1,113 | Research payment | Cash or cash equivalent | MICRA Device, Pacemakers | PSR-CVG | 2022 |
| 2022-03-02 | Acerta Pharma LLC | $5,421 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in | 2022 |
| 2022-03-01 | Cardiovascular Systems Inc. | $422 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-02-23 | Abbott Laboratories | $1,101 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | Amplatzer Amulet LAAO vs. NOAC (CATALYST) | 2022 |
| 2022-02-22 | Edwards Lifesciences Corporation | $7,800 | Research payment | Cash or cash equivalent | THE ENCIRCLE Trial (#2018-19) | 2022 | |
| 2022-02-22 | Boston Scientific Corporation | $837 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAPTOO | 2022 |
| 2022-02-22 | Boston Scientific Corporation | $761 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-02-21 | Boston Scientific Corporation | $28,488 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-02-21 | Boston Scientific Corporation | $1,332 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-02-16 | AstraZeneca Pharmaceuticals LP | $10,110 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2022 |
| 2022-02-16 | Abbott Laboratories | $5,341 | Research payment | Cash or cash equivalent | CARDIOMEMS Device, Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2022 |
| 2022-02-16 | Abbott Laboratories | $3,458 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, Structural Heart | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2022 |
| 2022-02-11 | Medtronic, Inc. | $250 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | LINQ Respiration | 2022 |
| 2022-02-02 | Abbott Laboratories | $2,562 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, Structural Heart | AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial | 2022 |
| 2022-02-01 | Cardiovascular Systems Inc. | $477 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-01-27 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | Onyx ONE Clear | 2022 |
| 2022-01-26 | Eli Lilly and Company | $246 | Research payment | In-kind items and services | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2022 | |
| 2022-01-25 | Esperion Therapeutics, Inc. | $613 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | $245 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-25 | Esperion Therapeutics, Inc. | $32 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-01-22 | Amgen Inc. | $7,340 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2022 |
| 2022-01-20 | AstraZeneca Pharmaceuticals LP | $952 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $15,188 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $5,000 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $5,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $1,514 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2022 |
| 2022-01-18 | Boston Scientific Corporation | $750 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2022 |
| 2022-01-14 | Cardiovascular Systems Inc. | $33,519 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
| 2022-01-13 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A POST-MARKET CLINICAL EVALUATION OF THE TREATMENT OF TIBIA FRACTURES WITH THE T2 ALPHA TIBIA NAILING SYSTEM | 2022 |
| 2022-01-13 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A POST-MARKET CLINICAL EVALUATION OF THE TREATMENT OF FEMUR FRACTURES WITH THE FEMORAL NAIL PIRIFORMIS FOSSA (PF) OF TH | 2022 |
| 2022-01-13 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | T2 Device, TRAUMA & EXTREMETIES | A POST-MARKET CLINICAL EVALUATION OF THE TREATMENT OF FEMUR FRACTURES WITH THE FEMORAL NAIL GREATER TROCHANTER (GT) OF T | 2022 |
| 2022-01-12 | PFIZER INC. | $8,400 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2022 |
| 2022-01-10 | Amgen Inc. | $4,773 | Research payment | In-kind items and services | Repatha Biological, Cardiology | 20170625_VESALIUS - CV | 2022 |
| 2022-01-04 | Eli Lilly and Company | $17,756 | Research payment | Cash or cash equivalent | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2022 | |
| 2022-01-03 | Cardiovascular Systems Inc. | $910 | Research payment | Cash or cash equivalent | Diamondback Coronary Device, Atherectomy Device | ECLIPSE | 2022 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Sartell, MN, county Stearns County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Sartell, MN | County Stearns County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 19,758 | 160,865 | 5,739,445 |
| Population, 2020 census P1 | 19,351 | 158,292 | 5,706,494 |
| Median age B01002 | 34.8 | 35.1 | 38.8 |
| Under 18 B01001 | 29.2% | 23.6% | 22.9% |
| 65 and over B01001 | 15.1% | 16.1% | 17.3% |
| Households B11001 | 7,630 | 61,403 | 2,307,955 |
| Foreign born B05002 | 4.2% | 7.9% | 8.7% |
| Median household income B19013 | $84,131 | $77,066 | $89,062 |
| Median family income B19113 | $117,973 | $99,842 | $113,993 |
| Per capita income B19301 | $42,415 | $38,286 | $48,237 |
| Poverty rate B17001 | 7.4% | 12.9% | 9.3% |
| Unemployment rate B23025 | 2.2% | 4.1% | 4.1% |
| Civilian labor force B23025 | 10,639 | 88,499 | 3,119,042 |
| Mean commute (minutes) B08013 | 18.8 | 21.7 | 22.7 |
| Bachelor's degree or higher B15003 | 40.9% | 28.8% | 39.4% |
| Housing units B25001 | 7,726 | 66,625 | 2,545,030 |
| Owner-occupied B25003 | 61.8% | 67.9% | 72.2% |
| Renters B25003 | 38.2% | 32.1% | 27.8% |
| Median home value B25077 | $297,300 | $273,400 | $329,300 |
| Median gross rent B25064 | $1,275 | $1,068 | $1,280 |
| White, not Hispanic B03002 | 85.1% | 80.2% | 75.9% |
| Black B03002 | 4.6% | 9.0% | 6.9% |
| Hispanic or Latino B03002 | 3.1% | 4.8% | 6.4% |
| Asian B03002 | 1.7% | 1.9% | 5.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Sartell, MN.
Comments